Clinical Trials
33 trialsNCT04107766 2026-04-17
NOLA (NeuWave Observational Liver Ablation) Registry
Ethicon, Inc.
Terminated
NCT05070247 2026-01-22
A Study of TAK-500 With or Without Pembrolizumab in Adults With Select Locally Advanced or Metastatic Solid Tumors
Takeda
Phase 1/2 Terminated
NCT00422877 2025-10-16
Taxoprexin® Treatment for Advanced Primary Cancers of the Liver, Gallbladder or Biliary Tract
American Regent, Inc.
Phase 2 Terminated
NCT05582018 2025-09-15
PANORAMA
Techsomed Medical Technologies LTD
Phase NA Terminated
NCT04502082 2025-09-08
Study of ET140203 T Cells in Adults With Advanced Hepatocellular Carcinoma (ARYA-1)
Eureka Therapeutics Inc.
Phase 1 Terminated
NCT00051532 2025-02-25
Seocalcitol Versus Placebo in Advanced Hepatocellular Carcinoma
LEO Pharma
Phase NA Terminated
NCT00051545 2025-02-25
Seocalcitol Versus Placebo in the Adjuvant Treatment of Hepatocellular Carcinoma
LEO Pharma
Phase 3 Terminated
NCT05497453 2025-02-03
MYCHELANGELO I
Omega Therapeutics
Phase 1/2 Terminated
NCT03685591 2024-06-26
PF-06952229 Treatment in Adult Patients With Advanced Solid Tumors
Pfizer
Phase 1 Terminated
NCT05061537 2024-04-12
Study of PF-07263689 in Participants With Selected Advanced Solid Tumors
Pfizer
Phase 1 Terminated
NCT03753789 2024-01-05
Ablation Confirmation Study
Ethicon, Inc.
Phase NA Terminated
NCT05363605 2023-12-19
A Study of [225Ac]-FPI-1966 in Participants With Advanced Solid Tumours
Fusion Pharmaceuticals Inc.
Phase 1/2 Terminated
NCT04311710 2023-02-24
CheckMate 76U
Bristol-Myers Squibb
Phase 1 Terminated
NCT01464593 2022-10-13
ABLATE
Imunon
Phase 2 Terminated
NCT03998033 2022-08-23
ET-109
Eureka Therapeutics Inc.
Phase 1 Terminated
NCT01402908 2022-06-23
PATRON
Cellxpert Biotechnology Corp.
Phase 3 Terminated
NCT02721056 2021-05-10
NBTXR3 Crystalline Nanoparticles and Stereotactic Body Radiation Therapy in the Treatment of Liver Cancers
Nanobiotix
Phase 1/2 Terminated
NCT04264754 2021-05-06
Characterization of Methylation Patterns in Hepatocellular Carcinoma
Nucleix Ltd.
Terminated
NCT03516695 2021-04-21
READ90Y
Boston Scientific Corporation
Terminated
NCT00503867 2020-12-10
SIR-Spheres® for the Treatment of Unresectable Hepatocellular Carcinoma
Sirtex Medical
Phase NA Terminated
NCT03644511 2020-08-21
SORAGO-HCC
Bayer
Terminated
NCT03349255 2019-07-01
Clinical Study of ET1402L1-CAR T Cells in AFP Expressing Hepatocellular Carcinoma
Aeon Therapeutics (Shanghai) Co., Ltd.
Phase 1 Terminated
NCT02690350 2018-05-16
An Open Study Assessing the Safety and Tolerability of U3-1784
Daiichi Sankyo
Phase 1 Terminated
NCT01668017 2017-08-23
A Multicentre, Open Label, Phase 1 Trial in Japan of the Mitogen Activated Protein Extracellular Signal Regulated Kinase (MEK) Inhibitor Pimasertib Given Orally to Subjects With Solid Tumors as Monotherapy
Merck KGaA, Darmstadt, Germany
Phase 1 Terminated
NCT02323906 2017-03-20
Safety and Efficacy Study of CC-122 Combined With Sorafenib for Primary Liver Cancer
Celgene
Phase 1 Terminated
NCT00332280 2013-03-20
Study to Evaluate the Clinical Benefit Response in Cancer Patients With Advanced Disease With AMT2003 Versus Placebo
Auron Healthcare GmbH
Phase 2/3 Terminated
NCT00405873 2013-03-20
Study to Evaluate Tumour Response in Cancer Patients With Advanced Hepatocellular Carcinoma (Liver Cancer) With AMT2003
Auron Healthcare GmbH
Phase 2 Terminated
NCT01009593 2012-09-10
Efficacy and Tolerability of ABT-869 Versus Sorafenib in Advanced Hepatocellular Carcinoma (HCC)
Abbott
Phase 3 Terminated
NCT01238653 2012-08-08
Feasibility of a Minimally Invasive Image-Guided Surgery System for Hepatic Procedures
Pathfinder Therapeutics
Terminated
NCT00568308 2011-06-15
PATHWAY
Progen Pharmaceuticals
Phase 3 Terminated
NCT00106054 2010-08-27
Neoadjuvant Colorectal Cancer With Unresectable Liver Metastases
Pfizer
Phase 2 Terminated
NCT00034333 2005-06-24
Safety and Efficacy of Doxorubicin Adsorbed to Magnetic Beads Vs. IV Doxorubicin in Treating Liver Cancer
FeRx
Phase 2/3 Terminated
NCT00057382 2005-06-24
T138067 Versus Doxorubicin in Chemotherapy-Naive, Unresectable, Hepatocellular Carcinoma Patients
Tularik
Phase 2/3 Terminated